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Abstract
AIM
To evaluate the impact of sepsis and non-communicable diseases (NCDs) on the
outcome of decompensated chronic liver disease (CLD) patients.
METHODS
In this cross-sectional study, medical records of patients with CLD admitted to
the Gastroenterology unit at the Aga Khan University Hospital were reviewed.
Patients older than 18 years with decompensation of CLD (i.e., jaundice, ascites,
encephalopathy, and/or upper gastrointestinal bleed) as the primary reason for
admission were included, while those who were admitted for reasons other than
decompensation of CLD were excluded. Each patient was followed for 6 wk after
index admission to assess mortality, prolonged hospital stay (> 5 d), and early
readmission (within 7 d).
RESULTS
A total of 399 patients were enrolled. The mean age was 54.3 ± 11.7 years and
64.6% (n = 258) were male. Six-week mortality was 13% (n = 52). Prolonged
hospital stay and readmission were present in 18% (n = 72) and 7% (n = 28) of
patients, respectively. NCDs were found in 47.4% (n = 189) of patients. Acute
kidney injury, sepsis, and non-ST elevation myocardial infarction were found in
41% (n = 165), 17.5% (n = 70), and 1.75% (n = 7) of patients, respectively. Upon
multivariate analysis, acute kidney injury, non-ST elevation myocardial
infarction, sepsis, and coagulopathy were found to be statistically significant
predictors of mortality. While chronic kidney disease (CKD), low albumin, and
high Model for End-Stage Liver Disease (MELD)-Na score were found to be
statistically significant predictors of morbidity. Addition of sepsis in conventional
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MELD score predicted mortality even better than MELD-Na (area under receiver
operating characteristic: 0.735 vs 0.686; P < 0.001). Among NCDs, CKD was found
to increase morbidity independently.

Manuscript source: Invited

Core tip: Chronic liver disease is one of the leading causes of mortality. Child-Pugh
and Model for End-Stage Liver Disease scores have been designed to predict the
outcome in cirrhotic patients. Infection and renal insufficiency can worsen the outcome
in cirrhotic patients. Myocardial infarction, sepsis,, and coagulopathy are associated with
poor outcomes in patients with cirrhosis. The addition of sepsis can improve the
predictability of the Model for End-Stage Liver Disease score as a prognostic marker for
mortality in hospitalized patients with liver cirrhosis. Presence of chronic kidney disease
increased the morbidity of cirrhotic patients. There is no direct impact of noncommunicable disease over mortality in hospitalized patients with liver cirrhosis.
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CONCLUSION
Addition of sepsis improved the predictability of MELD score as a prognostic
marker for mortality in patients with CLD. Presence of CKD increases the
morbidity of patients with CLD.
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INTRODUCTION
The massive global burden of chronic liver disease (CLD) has been well
documented[1], with more than one million deaths per year worldwide[2] making it the
14th leading cause of death globally[3]. Many prognostic models have been developed
over the years to help classify the severity of liver disease and direct the
aggressiveness of medical care. The Child-Pugh Turcotte (CTP) Score and the Model
for End-Stage Liver Disease (MELD) score are two of the most commonly used
scoring systems worldwide[4-6].
Child and Turcotte proposed the CTP score initially using nutritional status, the
presence of ascites, hepatic encephalopathy, total bilirubin, and albumin as
parameters to determine mortality risk in patients undergoing portosystemic shunt
surgery. Later, Pugh et al[4] modified it to its current version by replacing nutritional
status with prothrombin time or international normalized ratio (INR), making it the
most widely used scoring system for estimation of prognosis in CLD patients.
However, the subjectivity of variables (ascites, encephalopathy) as well as interlaboratory variability limited the accuracy of the CTP score, with the waitlist mortality
for liver transplantation continuing to rise[7].
MELD score was introduced primarily to determine the survival of patients
undergoing transjugular intrahepatic portosystemic shunt placement[5]. MELD score
incorporates total bilirubin, creatinine, and INR. It has not only become the mainstay
for prioritizing patients for liver transplant, but also for predicting mortality in nontransplant surgical procedures, alcoholic hepatitis, and acute variceal hemorrhage[6,8].
However, there are still several comorbidities such as hepatocellular carcinoma,
hepatopulmonary syndrome, and portopulmonary hypertension (HTN) that can
affect the prognosis of CLD patients and that are not taken into account by the MELD
score[9,10].
Several studies have been done on the MELD score with proposals made for
revision of the scoring system to include other factors to improve the predictive
accuracy of the score. Some of these include modified CTP, MELD-Na, Reweighted
MELD and the Refit MELD, which have been shown to be superior to the current CTP
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and MELD scores[11-14]. Such studies have led several leading researchers to investigate
other variables and scoring systems to better predict mortality in patients hospitalized
for decompensated CLD.
Acute kidney injury (AKI) is a devastating complication that is frequently
progressive and independently associated with mortality in a stage-dependent
fashion in CLD patients[15]. Bacterial infections are common in liver disease, especially
in decompensated patients. Infections increase the mortality four-fold in patients with
end-stage liver disease[16]. Inflammation stemming from infections plays a key role in
the outcome of cirrhosis. The presence of systemic inflammatory response syndrome
with or without infection is a major predictor of prognosis in CLD patients[17].
There is an alarming rise in the prevalence of non-communicable diseases (NCDs)
worldwide. Diabetes, HTN, cardiovascular diseases, chronic obstructive pulmonary
diseases, and cancers have emerged as leading causes of mortality globally[18]. In a
recent cohort of the Asian population, diabetes was found to impact mortality in
cirrhotic patients[19]. However, the effect of other NCDs on the outcomes of liver
disease has not been elucidated.
Charlson et al[20] proposed a comorbidity index to predict all-cause mortality on the
basis of a number of comorbid conditions. Seventeen different diseases, each allocated
a score from one to six, are incorporated in the Charlson comorbidity index. The total
sum gives the total burden of comorbidities in that patient[20]. Since the 1980s, the
score has been extensively used to estimate mortality in a different subset of cohorts
including liver disease patients[21,22]. However, the severity of liver disease was not
incorporated in those studies.
The aim of this study is to evaluate the impact of NCDs on the outcome of patients
admitted for decompensated CLD. We also aimed to construct a model over and
above the existing scoring system.

MATERIALS AND METHODS
Study design and settings
This study employed a cross-sectional design. Medical records of CLD patients who
were admitted to the Gastroenterology unit at the Aga Khan University Hospital in
Karachi, Pakistan were reviewed. Patients older than 18 years with decompensation
of CLD (i.e. jaundice, ascites, encephalopathy, and/or upper gastrointestinal (GI)
bleed) as the primary reason for admission were included. Those admitted for reasons
other than decompensation of CLD were excluded. Each patient was followed for 6
wk after index admission to assess mortality and morbidity. The study was conducted
after approval from the institutional ethical review committee.

Variables analyzed
(1) Demographics: age, gender, weight, duration of documented CLD, smoking, and
current alcohol use; (2) Clinical presentation: blood pressure, heart rate, temperature,
respiratory rate, Glasgow coma scale; (3) CLD complications/decompensation:
presence of jaundice, ascites, encephalopathy, esophageal varices, GI bleeding,
hepatorenal syndrome, spontaneous bacterial peritonitis, and hepatopulmonary
syndrome; (4) NCDs: Diabetes mellitus, HTN, chronic obstructive lung disease,
ischemic heart disease, congestive heart failure, peripheral vascular disease, chronic
kidney disease (CKD), cerebrovascular disease (prior strokes), acquired
immunodeficiency syndrome, cancer, dementia, connective tissue diseases, and peptic
ulcer disease; (5) Laboratory markers: complete blood count, electrolytes, liver
function tests, serum albumin, creatinine, prothrombin time, C-reactive protein; (6)
Scoring Systems: Child-Pugh Score, MELD score, MELD-Na score, and Charlson
comorbidity index. While calculating Charlson comorbidity index, patients with Child
A disease were given a score of 1 (mild), while those with Child B and C disease were
given a score of 3 (moderate to severe) as per standard score; and (7) Primary
outcome: To assess mortality within 6 wk of admission and morbidity defined as
either prolonged hospital stay > 5 d (120 h) or readmission within 7 d of the index
admission.

Operational definitions
Sepsis: Sepsis was defined as the presence of any source of infection along with at
least two of the following[23]: (1) Temperature > 38 °C (100.4 °F) or < 36 °C (96.8 °F); (2)
Heart rate > 90 bpm; (3) Respiratory rate > 20 or PaCO2 < 32 mmHg; and (4) Total
leukocyte count (TLC) > 12000/mm³, < 4000/mm³, or > 10% bands.
AKI: AKI was defined as per kidney disease: Improving Global Outcomes Acute
Kidney Injury Work Group, and revised consensus recommendations of the

WJH

https://www.wjgnet.com

946

December 27, 2018

Volume 10

Issue 12

Qazi Arisar FA et al. Sepsis and NCDs in cirrhosis

International Club of Ascites[24], i.e. increase in serum creatinine ≥ 0.3 mg/dL within 48
h; or a percentage increase serum creatinine ≥ 50% from the baseline which is known,
or presumed, to have occurred within the prior 7 d.

Statistical analysis
The sample size was calculated using Open Epi for proportion, using mortality rate
due to infection, and AKI between 36%-38% [16] . Taking into account the 95%
confidence interval (CI), 80% power, and an odds ratio (OR) of 1.5, the final sample
size was approximately 384 CLD patients.
Data were analyzed using Statistical Package for Social Sciences version 20. The
frequency for all variables was calculated. Data were expressed as a mean and
standard deviation for normally distributed continuous variables. The significance of
association was calculated using the Student t-test. Categorical variables were
recorded in their absolute value and analyzed using the chi-squared test. Univariate
analysis was used to identify parameters associated with mortality and morbidity.
Multiple logistic regressions were done in order to identify independent predictors of
poor outcome in these patients. These factors were incorporated in the existing MELD
score. Receiver operating characteristic curves of MELD, MELD-Na, and the new
score were made. Significance tests and CIs were assessed through the nonparametric
bootstrap. The area under the curve was compared between the three scores. Fisher
exact test was used to determine the association of NCDs with predictors of mortality.
All P values were two-sided and a P value of < 0.05 was considered statistically
significant.

RESULTS
Demographics
Records of 399 patients admitted primarily due to decompensation of liver disease
were reviewed. Mean age was 54.3 ± 11.7 years and 64.6% (n = 258) of patients were
male. Hepatitis C was found to be the leading cause of CLD. The length of hospital
stay of more than five days was 18%, while readmission rate within 1 wk was 7%. Sixweek mortality was observed in 13% (n = 52) of patients. Table 1 describes the
demographic details of patients.
NCDs were present in 47.4% (n = 189) of patients. AKI, sepsis, and non-ST
elevation myocardial infarction (NSTEMI) were present in 41% (n = 165), 17.5% (n =
70), and 1.75% (n = 7) of patients, respectively.

Factors predicting mortality
Upon univariate analysis, hypotension, tachycardia, tachypnea, hypoxia, NSTEMI,
sepsis, renal insufficiency, encephalopathy, pneumonia, anemia, leukocytosis
coagulopathy, high CTP and MELD scores, and frequent admissions in the last 1 to 3
mo were found to be associated with 6 wk mortality.
Upon multivariate analysis, sepsis (OR = 6.50; 95%CI: 3.007-14.06; P < 0.001), AKI
(OR = 2.69; 95%CI: 1.17-6.20; P = 0.02), and INR (OR = 1.75; 95%CI: 1.14-2.69; P <
0.001) were significant independent predictors of mortality (Table 2). Figure 1 shows a
flow diagram of 6 wk mortality for patients with advanced cirrhosis and concomitant
sepsis based on the logistic regression model. Sepsis, AKI, and INR were used in a
hierarchical pattern based on the OR.

Factors predicting morbidity
Upon multivariate analysis, CKD, low albumin, and high MELD-Na scores were
found to be independent factors in predicting morbidity (Table 3).

Factors predicting both mortality and morbidity
Upon multivariate analysis, CKD, high TLC, and high Child class were found to affect
both mortality and morbidity (Table 4).

Addition of sepsis in MELD score
Once the value of sepsis was determined as a significant independent predictor of
mortality based on multivariate analysis, we tried to formulate a new score by adding
a factor of 6.5 into existing MELD scores. This factor was derived from the odds ratio
of sepsis for mortality upon multivariate analysis. The new score labeled as MELDsep was found to predict mortality better than MELD and MELD-Na as depicted by
the area under receiver operating characteristic of 0.735 for MELD-sep in contrast
with 0.686 for MELD-Na and 0.671 for MELD score (Figure 2).

Impact of NCDs
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Table 1 Baseline demographic details
n (%) or
Variables
mean ± SD
Age (yr)

54.56 ± 11.74

Gender

Etiology (viral)

Male

258 (64.6)

Female

136 (34.4)

Hepatitis C

260 (65.1)

Hepatitis B

31 (7.7)

Hepatitis B + Hepatitis D

12 (3)

Hepatitis B + Hepatitis C

6 (1.5)

Non-B, Non-C

61 (15.2)

(Unknown etiology)
Alcohol

20 (5)

Autoimmune hepatitis

8 (2)

Hemochromatosis

1 (0.25)

Duration of chronic liver disease (yr)
NCDs

4.25 ± 3.71
Diabetes

Infections on admission

148 (37)

Hypertension

96 (24)

Chronic kidney disease

30 (7.5)

Ischemic heart disease

23 (5.7)

Chronic obstructive pulmonary disease

13 (3.2)

Sepsis

70 (17.5)

Lower respiratory tract infection

24 (6)

Urinary tract infection

30 (7.5)

Non-ST Elevation myocardial infarction

7 (1.75)

Stroke

3 (0.75)

Decompensation on admission

Investigations

Child class

Prognostic scores

WJH
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Ascites

300 (75.1)

Presence of esophageal/gastric varices

235 (58.8)

Portosystemic encephalopathy

170 (42.6)

Acute kidney injury

165 (41.3)

Upper GI bleed

118 (29.5)

Hepatocellular carcinoma

98 (24.5)

Hepatorenal syndrome

86 (21.5)

Spontaneous bacterial peritonitis

76 (19)

Hepato-hydrothorax

12 (3)

Hemoglobin (g/dL)

9.81 ± 2.17

Total leukocyte count (× 109/L)

9.87 ± 6.17

Platelets (× 109/L)

121.29 ± 108.12

Prothrombin time (s)

17.37 ± 7.87

International normalizing ratio

1.63 ± 0.65

Creatinine (mg/dL)

1.65 ± 1.37

Sodium (mmol/L)

132.3 ± 7.62

Potassium (mmol/L)

4.17 ± 0.88

pH

7.37 ± 0.12

Bicarbonate (mmol/L)

20.13 ± 4.79

Total bilirubin (mg/dL)

5.47 ± 7.57

Alanine transaminase (IU/L)

78.7 ± 128.21

Gama glutamyl transferase (IU/L)

119.26 ± 159.87

Alkaline phosphatase (IU/L)

178.35 ± 133.8

Albumin (g/dL)

2.59 ± 0.58

A

39 (9.8)

B

142 (35.6)

C

218 (54.6)

MELD score

18.0 ± 8.55
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Outcomes

MELD-Na

21.73 ± 8.31

Charlson index

4.21 ± 1.63

Charlson age adjusted score

5.33 ± 2.20

Mortality

52 (13)

Prolong stay

72 (18)

Readmission

28 (7)

NCDs: non-communicable diseases; GI: gastrointestinal; MELD: Model for End-Stage Liver Disease.

NCDs were found to be associated with an increased readmission rate (28.6% without
NCDs vs 71.4% with NCDs; P = 0.03). However, there was no effect on length of stay
(length of stay > 5 d in 51.4% without NCDs vs 48.6% with NCDs; P = 0.45). Upon
multivariate analysis, among all NCDs, only CKD was directly related with increased
morbidity (OR = 3.18; 95%CI: 1.30-7.82; P = 0.01). Moreover, the presence of NCDs
was not found to be an independent predictor of mortality in our series (mortality rate
of 12.4% without NCDs vs 13.9% with NCDs; P = 0.65). Similarly, the presence of
multiple comorbid conditions did not appear to impact the mortality directly
(mortality rate of 12.2% without NCDs vs 14.1% with 2 or fewer NCDs vs 15.6% with 3
or more NCDS; P = 0.97). However, the presence of NCDs was directly related with
NSTEMI, which was a major predictor of mortality in our study (Table 5). Similarly,
Charlson comorbidity index was used to calculate the burden of NCDs in our
patients, and this index did not appear to predict the outcome in cirrhotic patients.

DISCUSSION
Decompensated liver disease is a state of organ failure related to multi-organ
consequences such as encephalopathy, renal insufficiency, volume overload, GI
bleeding, infections, and frailty[25-28]. In this study of hospitalized decompensated
cirrhotic patients, we evaluated the impact of sepsis and NCDs on patient outcome.
Traditionally, CTP and MELD scores have been used to predict the mortality in
cirrhotic patients. However, the group of patients used to create and validate the
MELD score was devoid of acute reversible complications such as sepsis[29]. Infections
significantly increase the mortality in end-stage liver disease with some studies
reporting a 30% death rate in 1 mo[16]. Prevention and treatment of sepsis were shown
to reduce mortality in patients with cirrhosis and AKI [17] . AKI is a common and
overwhelming complication in patients with end-stage liver disease. Belcher et al[15]
also showed AKI to be associated with high mortality and complications in
hospitalized patients with cirrhosis. Our study found that AKI, myocardial infarction,
sepsis, and coagulopathy on admission were associated with high mortality in
cirrhotic patients.
Interestingly, the MELD and Charlson comorbidity index scores were not
associated with high mortality in our analysis. However, high Child class appeared to
affect both mortality and morbidity. Based on our observations, we propose that the
addition of sepsis as a factor in the MELD score gives a better prediction of mortality
as compared to conventional MELD and MELD-Na scores in CLD patients admitted
with acute decompensation. We also found that CKD, low albumin, and high MELDNa scores were able to predict morbidity.
Chirapongsathorn et al[30] and Shu et al[31] related longer hospital stays with a high
rate of 30-d readmission while Masadeh et al[32] found the opposite relationship. In our
analysis, prolonged hospital stay was associated with subsequent early readmission
upon univariate analysis but did not stand out as an independent factor upon
multivariate analysis.
The prognostic value of chronic NCDs in cirrhotic patients has not been extensively
studied. Recently, diabetes has been associated with high mortality[19,33,34], higher
readmission rate [35] , and a major factor in determining liver-related outcomes in
cirrhotic patients[36]. We were unable to relate diabetes directly to mortality and
morbidity in our series. However, among NCDs, CKD was found to directly predict
morbidity in our series. Moreover, the presence of NCDs was associated with
NSTEMI, which was one of the major predictors of mortality in our cohort. This
observation indicates NCDs as an important factor that could influence the outcome
of CLD patients independent of well-known prognostic variables incorporated in
Child-Pugh and MELD scores for advanced liver disease patients.
Despite previous studies supporting the use of the Charlson comorbidity index for
prediction of poor outcome in CLD patients[21,22], our study did not find a direct
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Figure 1

Figure 1 Flow diagram of 6 wk mortality for patients with advanced cirrhosis and concomitant sepsis based
on the logistic regression model. AKI: Acute kidney injury; INR: International normalized ratio.

relationship between Charlson comorbidity index and morbidity upon multivariate
analysis. This could be due to the difference between patient characteristics. We
selectively enrolled patients who were admitted due to decompensated liver disease
while previous studies included patients who were labeled as cirrhotic in their
database regardless of compensation status[21,22]. Moreover, the follow-up period was
longer in the Danish cohort[22].
The present study takes into account readmissions at our center. The possibility of
readmissions at other centers was not accounted for. Other limitations include the
cross-sectional design, shorter follow-up, and single center focus. Further large-scale
multicenter studies with a longer follow-up would be helpful in strengthening the
impact of NCDs and sepsis on the determination of outcome in hospitalized cirrhotic
patients.
In conclusion, the addition of sepsis improves the predictability of the MELD score
as a prognostic marker for mortality in patients with decompensated CLD. Presence
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Table 2 Multivariate analysis of factors predicting 6 wk mortality in chronic liver disease
patients
OR (95%CI)
NSTEMI

Sepsis

AKI

No

1

Yes

16.03 (2.01-127.46)

No

1

Yes

6.50 (3.01-14.06)

P value

0.009

< 0.001

No

1

Yes

2.69 (1.17-6.20)

0.02

1.75 (1.14-2.69)

< 0.001

INR

NSTEMI: non-ST-elevation myocardial infarction; AKI: acute kidney injury; INR: international normalized
ratio; OR: odds ratio; CI: confidence interval.

of CKD increases morbidity of patients with CLD.
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Table 3 Multivariate analysis of factors predicting morbidity
OR (95%CI)
CKD

P value

No

1

Yes

3.18 (1.30-7.82)

0.01

MELD-Na

1.05 (1.01-1.08)

0.005

Albumin

0.55 (0.32-0.92)

0.02

Prolonged hospital stay > 5 d (120 h) or readmission within 7 d of the index admission; CKD: chronic kidney disease; MELD: Model for End-Stage Liver
Disease; OR: odds ratio; CI: confidence interval.

Table 4 Multivariate analysis of factors predicting both mortality and morbidity
OR (95%CI)
CKD

P value

No

1

Yes

3.12 (1.21-8.06)

0.01

TLC

1.08 (1.03-1.12)

< 0.001

Child Class

3.57 (2.20-5.79)

< 0.001

CKD: chronic kidney disease; TLC: total leukocyte count; OR: odds ratio; CI: confidence interval.

Table 5 The relationship between predictor of mortality and non-communicable diseases, n (%)
NCDs

NSTEMI

Yes

No

210 (52.6)

189 (47.3)

P value

7 (3.3)

0

0.01

Sepsis

31 (14.8)

39 (20.6)

0.14

AKI

92 (44.7)

76 (40.2)

0.41

NSTEMI: non-ST-elevation myocardial infarction; INR: international normalized ratio; AKI: acute kidney injury; NCDs: non-communicable diseases.

Figure 2

Figure 2 Receiver operating characteristic curve shows 6 wk mortality prediction of MELD-Sep vs MELD and MELD-Na. MELD: Model for End-Stage Liver
Disease.
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ARTICLE HIGHLIGHTS
Research background
Patients with decompensated chronic liver disease (CLD) are at high risk of complications.
Various scores have been used to classify the severity of liver disease and to predict mortality.
Recently, diabetes was found to impact mortality in cirrhotic patients. However, the impact of
other comorbidities on mortality and morbidity has not been studied. Moreover, the impact of
sepsis on available predictability scores has not been determined.

Research motivation
Given the limitations with the use of Child-Pugh and Model for End-Stage Liver Disease
(MELD) scores, we wanted to come up with a new score to predict mortality and morbidity.

Research objective
The objective for this study included determination of sepsis, non-communicable diseases
(NCDs), and acute kidney injury (AKI) in patients admitted with decompensated liver disease,
along with their impact of NCDs on mortality and morbidity parameters. We also wanted to
evaluate whether the addition of any other variable makes MELD a better tool as a prognostic
marker.

Research methods
We performed a retrospective analysis of medical records of patients with CLD admitted at the
Aga Khan University Hospital. All adult patients with decompensation of CLD (i.e., jaundice,
ascites, encephalopathy, and/or upper gastrointestinal (GI) bleed) as the primary reason for
admission were included. Multivariate analysis was performed to assess predictors of 6 wk
mortality, prolonged hospital stay (> 5 d), and early readmission (within 7 d).

Research results
Six-week mortality rate was 13%. Prolonged hospital stay and readmission rates were 18% and
7%, respectively. NCDs were present in 47.4% of patients. AKI, sepsis, and NSTEMI were
present in 41%, 17.5%, and 1.75% patients, respectively. Factors associated with mortality
included AKI, NSTEMI, sepsis, and coagulopathy. The factors found responsible for morbidity
included chronic kidney disease (CKD), low albumin, and high MELD-Na score. By adding
sepsis to the conventional MELD score, the predictability of mortality increased significantly.
CKD was found to impact morbidity independently.

Research conclusion
This study highlighted multiple factors associated with early mortality, readmission, and
prolonged hospital stay. This study also determined the significance of the addition of sepsis in
the MELD score to improve its predictability as a prognostic marker for mortality in patients
with decompensated CLD. Presence of CKD increased morbidity of patients with CLD.

Research perspective
We need to amend factors linked to mortality, readmission, and prolonged stay not only to
control mortality and morbidity, but also to minimize the cost burden by patients.
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